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Background: Long-term lung allograft survival is limited by bronchiolitis obliterans syndrome (BOS). Mannose
binding lectin (MBL) belongs to the innate immune system, participates in complement activation, and may
predispose to graft rejection. We investigated mannose binding (MBL) during cold ischemia and in tissue samples
from explanted lungs with BOS, and assessed MBL and complement proteins in plasma post-lung transplantation
relative to BOS staging.
Methods: MBL was detected by immunohistochemistry lung tissue at the time of cold ischemia and in samples
with BOS. MBL was assayed in the peripheral blood of 66 lung transplant patients transplanted between 1990–2007.
Results: MBL localized to vasculature and basement membrane during cold ischemia and BOS. Patients further out
post-lung transplant> 5 years (n = 33), had significantly lower levels of MBL in the blood compared to lung
transplant patients< 5 years with BOS Op-3 (n = 17), 1738 ± 250 ng/ml vs 3198 ± 370 ng/ml, p = 0.027, and similar
levels to lung transplant patients< 5 years with BOS 0 (n = 16), 1738 ± 250 ng/ml vs 1808 ± 345 ng/ml. MBL levels in
all BOS 0 (n = 30) vs. all BOS Op-3 (n = 36) were 1378 ± 275 ng/ml vs. 2578 ± 390 ng/ml, p = 0.001, respectively. C3
plasma levels in BOS 0 (n = 30) vs. BOS Op-3 (n = 36) were 101 ± 19.8 mg/ml vs. 114 ± 25.2 mg/ml, p = 0.024,
respectively.
Conclusions: MBL localizes within the lung during graft ischemia and BOS, higher levels of plasma MBL are
associated with BOS Op-3 and< 5 years post-transplant, and higher level of plasma complement protein C3 was
associated with BOS Op-3 clinical status. MBL may serve as a biomarker for poorer outcome post-lung
transplantation.
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Lung transplantation for end-stage lung disease is a suc-
cessful treatment, however, long-term survival is limited by
bronchiolitis obliterans (BOS). The 5-year probability of
freedom from BOS is 15-37%, and once diagnosed, actuar-
ial survival is 26-43% [1]. Acute rejection predisposes to
chronic lung allograft rejection, and although acute rejec-
tion is reversible, repeated injury to the lung allograft by
alloimmune and non-alloimmune pathways, will promote
airway fibrosis. Innate, adaptive, and humoral immunity* Correspondence: INeuringer@Partners.org
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reproduction in any medium, provided the oralso compound airway injury through concurrent infection,
Th1 cytokines and T cells, and antibody and complement-
mediated injury [2-4]. Acute lung allograft rejection
while typically identified by infiltrating T cells, may
progress to include peribronchial and perivascular
infiltrates with B cells and neutrophils, as well as C3d
and C4d complement [5-8]. Antibody-mediated rejec-
tion is increasingly recognized as a contributing factor
in chronic graft injury and bronchiolitis obliterans and
is under intense investigation in thoracic transplant-
ation [9].
Mannose binding lectin (MBL), a member of the col-
lectin family (surfactant proteins A and D, mannose
binding lectin, MBL) participates in activation of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics of patients>5 years post-transplant,
compared to patients< 5 years post-transplant
< 5 BOS 0 < 5 BOS Op-3 > 5 BOS 0 > 5 BOS Op-3
n 16 17 12 21
Average age at
transplant (all
diagnosis groups)
37.9 36.7 36.0 33.5
Average age at
transplant (CF)
33.6 25 33.5 31.4
Male/Female 8/8 12/5 4/8 10/11
Diagnosis
CF 13 11 8 16
Bronchiectasis
or PCD
0 0 1 2
COPD or alpha1 1 3 1 2
IPF or sarcoid 2 2 1 1
PH 0 1 1 0
Single lung 0 1 1 2
Double lung 16 16 11 19
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tive and innate immunity [10]. While surfactant proteins
A and D may be protective to the lung allograft after
lung transplantation, as reduced levels are associated
with BOS [11], MBL may be either protective or harmful
depending upon infectious or autoimmune risk. Pro-
duced by the liver and secreted into the circulation,
MBL is a pattern recognition molecule which binds to
pathogens via carbohydrate recognition domains which
complex with D-mannose, N-acetylglucosamine, and
glucose, activating the lectin pathway of complement
[12-14]. Upon recognition of appropriate carbohydrate
substrates, MBL binding activates MBL-associated serine
protease-2 (MASP-2), with subsequent cleavage of C4
and C2, generation of the C3 convertase C4b2a, and
complement activation [15-18]. Low serum MBL levels,
often due to genetic polymorphisms, have been asso-
ciated with increased risk of infection, more severe
manifestation of cystic fibrosis lung disease, and auto-
immunity, while high levels exacerbate inflammatory
diseases and diabetic nephropathy [19-28].
Studies examining the role of MBL in solid organ
transplantation have focused mostly upon ischemia-
reperfusion injury (IRI), finding that MBL binds to IgM
during IRI in experimental models [29]. MBL deposition
was observed in association with gastrointestinal and
renal transplantation-related ischemia [30-32]. The few
studies addressing the role of recipient MBL levels upon
long-term allograft survival have identified a detrimental
effect associated with elevated MBL levels [33,34]. Stud-
ies addressing MBL and lung transplantation have
yielded conflicting results, finding increased CMV infec-
tion and survival with MBL deficiency [35], high MBL
levels associated with worse survival [36], yet low levels
of MBL within the airways of patients with BOS [37].
We hypothesize that MBL is deposited within injured
lung allograft tissue at the time of transplantation as well
as BOS, and elevated in the plasma of patients with
bronchiolitis obliterans syndrome (BOS). MBL levels in
the plasma of lung transplant patients> 5 years post-
transplant with BOS 0 (n = 12) and BOS Op-3 (n = 21)
were compared to MBL levels in patients< 5 years with
BOS 0 (n = 16) and BOS Op-3 (n = 17).
Methods
Patient population - In compliance with IRB approved
protocols, patients were enrolled through routine clinic
appointments, with peripheral blood samples collected
during the year 2007 and BOS staging and data analysis
performed in 2008. All patients older than 18 years of
age were eligible except retransplant. Patients comprised
a group> 5 years post-transplant (1990–2003), and a re-
cently transplanted group, < 5 years (2003–2007). A
total of 60 patients are alive from the post-transplantgroup transplanted> 5 years ago, of whom 33 patients
were enrolled. In the< 5 years post-transplant, 2003–
2007, 54 patients were alive and 33 patients were en-
rolled form this recent transplant cohort. Patients were
staged for BOS according to ISHLT criteria. Characteris-
tics of the patient groups are demonstrated in Table 1.
Immunohistochemistry – Surgical biopsy tissue sam-
ples were analyzed for MBL in 1 ) lung allograft tissue
from patients at the time of lung implantation, parallel-
ing cold ischemia, 2) explanted lungs with bronchiolitis
obliterans, and 3) lung tissue with diffuse alveolar dam-
age from non-lung transplant patients, serving as a posi-
tive control. Tissue was obtained in accordance with IRB
protocols in place for sampling of lung tissue during cold
ischemia, bronchiolitis obliterans in explanted lungs, and
diffuse alveolar damage, granted through UNC Depart-
ment of Pathology and UNC Cystic Fibrosis Center.
Human lung tissue was fixed in formaldehyde and em-
bedded in paraffin. Antigen retrieval was performed.
Endogenous peroxidases were blocked. Anti-mannose-
binding lectin (human), clone HYB 131–01 (The Anti-
body Shop, Assay Designs, Ann Arbor, MI) was applied
at a dilution of 1:200. Secondary biotinylated donkey-
anti-mouse antibody was applied at 1:4000 (Jackson
Immunoresearch, West Grove, PA). Streptavidin-horse-
radish peroxidase was applied, followed by diaminobenzi-
dine (DAB) detection and methylene green counterstain.
Semi-quantitative morphometric analyses of percent vas-
culature, airway basement membranes, and alveolar-
capillary junctions staining positive per slide were per-
formed by a blinded reviewer.
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C3, and C4 levels were determined in the peripheral
blood of all 66 lung transplant patients studied. Periph-
eral blood was obtained during routine clinic appoint-
ments from 33 post transplant patients transplanted
within the past 5 years, and 33 post transplant patients
transplanted> 5 years. Patients were staged for BOS
according to ISHLT BOS Staging criteria. Blood was
assayed for MBL (Mayo Medical Labs, Rochester, MN,
range 5 ng-4000 ng/ml), C3 (88-171 mg/dl) and C4 (15-
48 mg/dl) (McClendon Labs, UNC Healthcare, Chapel
Hill, NC0. As noted the upper limit of detection for the
MBL assay was 4000 ng/ml, thus those with levels above
4000 ng/ml were assigned a level of 4000 ng/ml.
Statistics
Data are represented as mean ± standard deviation. Stat-
istical analysis was performed using SigmaPlot, Systat
Software (San Jose, CA). A two-tailed Student’s t test
was used to compare MBL levels normally distributed
between experimental groups. For data not normally dis-
tributed, non-parametric testing was performed using
Mann–Whitney rank sum test.
Results
1. Immunohistochemistry for MBL at the time of lung
allograft implantation, from explanted lung allografts
with BOS, and non-transplanted lung tissue with
diffuse alveolar damage. Immunohistochemistry for
MBL was performed on sections of lung allograft
tissue from patients at the time of lung allograft
implantation paralleling cold ischemia, (n = 6)
(Figure 1), explanted lung tissue from patients
retransplanted for bronchiolitis obliterans syndrome
(BOS, n = 8) (Figure 2) and non-transplant patients
with diffuse alveolar damage (DAD, n = 6) (Figure 3),
in accordance with IRB protocols. MBL deposition
was detected in all cold ischemia samples, localizing
to vasculature (80.1 ± 12%), bronchial epithelial
basement membranes (72.6 ± 11%), and along
alveolar/capillary membrane (33.4 ±6%). BOS
specimens demonstrated MBL along vasculature
(88.5 ±8%), remnant bronchiolar basement
membranes (52.3 ±15%), and alveolar/capillary
basement membranes (18.4 ±6%). DAD tissue
exhibited fainter deposition along vascular structures
(27.7 ±11%) and bronchiolar basement membranes
(54.3 ± 8%). Airway epithelial cells did not stain
positive in any tissue specimens. These data
demonstrate that MBL is widely distributed in
allografted lung tissue at the time of transplantation
as well as in chronic lung allograft rejection,
localizing to basement membrane structures.Ongoing activation of the lectin complement
pathway may support innate immune responses and
complement binding, contributing to graft injury.
2. MBL levels in the peripheral blood after lung
transplantation.
A. Long-term> 5 years post-lung transplant (n = 33)
patients, irregardless of BOS stage, had significantly
lower levels of MBL in the blood compared to lung
transplant patients< 5 years with BOS Op-3
(n = 10), 1738 ± 250 ng/ml vs 3198 ± 370 ng/ml,
p = 0.027, and similar levels to lung transplant
patients< 5 years with BOS 0 (n = 12),
1738 ± 250 ng/ml vs 1808 ± 345 ng/ml. Similarly,
patients with BOS 0< 5 years post-lung transplant
had significantly lower levels of MBL compared to
lung transplant patients< 5 years with BOS Op-3,
1808 ± 345 ng/ml vs. 3198 ± 370 ng/ml, p = 0.009
(Figure 4A). Approximately 4/33 (12%) of
patients> 5 years post-transplant were MBL
deficient (< 5 ng/ml), compared to 0/33 of
patients< 5 years post-transplant (p = 0.057).
B. Within the long-term> 5 years post-transplant
group, patients with BOS 0 (n = 12) had significantly
lower levels of MBL compared to those with BOS
Op-3 (n = 21), MBL level 1,048 ± 288 ng/ml vs
2186 ± 333 ng/ml, p =0.007, (Figure 4B).
C. Comparing all patients with BOS 0 (n = 30) vs.
BOS Op-3 (n = 36), BOS 0 patients had significantly
lower MBL, 1378 ± 275 ng/ml vs. 2578 ± 390 ng/ml,
p = 0.001, (Figure 4C).
3. Assessment of MBL levels compared to time post-
transplantation. MBL levels were compared to time
post-transplantation by linear regression in order to
determine if there was a significant effect of time post-
transplant. All 66 MBL levels obtained were analyzed
compared to a range of 2–22 years post-transplant. The
resulting values were R=0.31, R2=0.10, and p=0.009,
suggesting that MBL levels do decrease over time but
that the correlation is fair at best.
4. Complement levels in the peripheral blood after
lung transplantation. Comparing all patients with
BOS 0 (n = 30) vs. BOS Op-3 (n = 36), BOS 0
patients showed significantly lower C3,
101 ± 19.8 mg/ml vs. 114 ± 25.2 mg/ml, p = 0.024,
respectively, (Figure 5A). There were also trends
toward lower C3 levels in the cohorts divided by
transplant time (< 5 vs> 5 years). Within the long-
term> 5 years post-transplant group, patients with
BOS 0 (n = 12) had significantly lower levels of C4
compared to those with BOS Op-3 (n = 21), C4 level
21.6 ± 5.2 mg/ml vs 28.7 ± 6.3 mg/ml, p = 0.038
(Figure 5B). There were also trends toward lower C4
levels in BOS 0 vs BOS p-3 in those <5 yrs from
transplant.
Figure 1 Immunohistochemistry for mannose binding lectin (MBL) in lung allograft tissue (10X) during cold ischemia as detected by
anti-MBL antibody (mouse anti-human), DAB, and methylene green counterstain. MBL binds to airway basement membrane (star), A,
alveolar capillary junctions (star), C, and endothelium (star) E. Isotype controls (mouse IgG1, κ) shown in B, D, and F, respectively.)
Figure 2 Immunohistochemistry for mannose binding lectin (MBL) in lung allograft tissue (10X) in explanted lung allograft tissue with
bronchiolitis obliterans as detected by anti-MBL antibody (mouse-anti-human), DAB, and methylene green counterstain. MBL binds to
remnant airway basement membrane(star), A and C, and vasculature (star), E. Isotype controls (mouse IgG1, κ) shown in B, D, and F, respectively.
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Figure 3 Immunohistochemistry for mannose binding lectin (MBL) in lung allograft tissue (10X) in lung biopsies with non-transplant
diffuse alveolar damage as detected by anti-MBL antibody (mouse-anti-human), DAB, and methylene green counterstain. MBL binds to
airway basement membrane and alveolar spaces (star), A. Isotype control (mouse IgG1, κ) shown in B.
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Innate immunity, encompassing anti-microbial responses,
Toll-like receptors, complement, interleukin-1, macro-
phages, neutrophils, dendritic cells, and NK cells, is an
area of intense investigation in solid organ transplantation.
Mannose binding lectin (MBL) participates in the lectin
pathway of complement activation and innate immunity,
binds to apoptotic cells and microbes, and modulates in-
flammation. Although protective in enhancing responses
to microbes, we hypothesize that elevated levels of MBL
may contribute to allograft injury and bronchiolitis oblit-
erans syndrome (BOS) after lung transplantation. There-
fore MBL levels in patients> 5 years post-transplant and
patients with BOS 0 will be reduced compared to patients
transplanted< 5 years and patients with BOS Op-3.
Firstly, we have identified MBL binding to graft
endothelial surfaces and airway basement membranes
during ischemia-reperfusion and bronchiolitis obliter-
ans, demonstrating the presence of MBL during initial
implantation and during chronic alloimmune injury.
Secondly, we have determined that patients> 5 years
post-transplant had significantly lower levels of MBL
compared to those less than 5 years post-lung trans-
plantation. Thirdly, within each group, those with
BOS 0 had significantly lower MBL levels compared
to those with BOS Op-BOS 3. Fourthly, C3 comple-
ment levels were significantly lower in BOS 0 patients
compared to those with BOS O –Op, and C4 comple-
ment levels were significantly lower in BOS 0 patients
who were> 5 years post-transplant. These data fur-
ther the evidence for innate immune activation coex-
isting with adaptive immune responses, and suggest
that components of the complement system may im-
pact upon long-term graft survival and bronchiolitis
obliterans syndrome. Furthermore, in the> 5 year
post-transplant group, 12% had levels below detection.
This constitutes a significantly greater than the esti-
mated prevalence of functional MBL deficiency than
in the general population ~ 5%.Mannose binding lectin, as a member of the collectin
family, participates in host immunity and opsonization
of bacteria, playing a role in autoimmunity, cardiovascu-
lar disease, and sepsis. As a member of the collectin
family involved in host defense, MBL deposition may be
expected in the lung during injury or inflammation,
however, it has not been demonstrated in lung tissue
sections previously. Evidence from experimental studies
suggests that alloantibody binding to endothelial cells
promotes complement activation, with subsequent bind-
ing of MBL to carbohydrates on the Fc portion of the
antibody [38]. Members of the collectin family including
MBL and H-ficolin have been associated with antibody-
mediated rejection and ischemia-reperfusion in clinical
studies and experimental models outside the arena of
lung transplant. In renal transplant patients, MBL was
present during ischemia-reperfusion and delayed renal
graft function [39,40], and H-ficolin present during rou-
tine surveillance kidney biopsies [41]. In experimental
models, MBL deposited during renal ischemia-
reperfusion was inhibited by C1q inhibitor infusion [39]
which achieved graft protection. In a cardiac model of
antibody-mediated rejection, MBL contributed to C4d
deposition, as in the absence of MBL, complement and
non-complement fixing antibodies were unable to cause
C4d deposition [42]. Our finding of MBL deposition in
ischemia-reperfusion, diffuse alveolar damage, and bron-
chiolitis obliterans are in keeping with these studies.
In contrasting patients> 5 years post-transplant and
recently transplanted patients, lower MBL levels trended
down the longer time post-transplant, however, MBL
level and time post-transplant were only fairly correlated
per linear regression analysis. In addition, those with
BOS 0 had the lowest levels of MBL within each of the
groups compared to those with BOS Op −3. Studies of
the role of MBL in solid organ transplantation have
identified unique features associated with differing MBL
levels and genotypes. Low levels of MBL were associated
with a higher risk of infection after liver transplantation
Figure 5 Comparing all patients with BOS 0 (n = 29) vs. BOS
Op-3 (n = 36), BOS 0 patients had significantly lower C3, 104 mg/
ml vs. 114 mg/ml, p = 0.024, respectively, A. Within the long-term
survivors cohort, patients with BOS 0 (n = 12) had significantly lower
levels of MBL and C4 compared to those with BOS Op-3, C4 level
21.6 mg/ml vs 28.7 mg/ml, p = 0.038, B.
Figure 4 Mannose binding lectin levels in the peripheral blood
of lung transplant patients transplanted > 5 years or < 5 years,
with BOS 0 compared to BOS Op-3. Long-term > 5 years post-
lung transplant patients (n = 33) had significantly lower levels of
MBL in the blood compared to lung transplant patients < 5 years
with BOS Op-3 (n = 10), 1738 ng/ml vs 3198 ng/ml, p = 0.027, A.
Within the long-term > 5 years post-transplant cohort, patients with
BOS 0 (n = 12) had significantly lower levels of MBL compared to
those with BOS Op-3 (n = 21), MBL level 1,048 ng/ml vs 2186 ng/ml,
p =0.007, B. Comparing all patients with BOS 0 (n = 29) vs. BOS Op-
3 (n = 36), BOS 0 patients had significantly lower MBL and C3, 1378
ng/ml vs. 2578 ng/ml, p = 0.001, C.
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tion from alloimmune injury. MBL deficiency was also
associated with fewer episodes of acute graft rejection after
cardiac transplantation [44]. Similarly, low serum MBL
proved protective in kidney and kidney-pancreas trans-
plantation [33,34]. Studies addressing MBL and lung trans-
plantation found that donor X-allele and LXPA haplotype,
associated with low serum MBL production, conferred allo-
graft protection from BOS [45], and similar to our findings,
that high levels of MBL were associated with poorer out-
comes after lung transplantation [36]. Lastly, our survey of
C3 and C4 levels demonstrated significantly lower C3 levels
associated with BOS 0, and long-term survivors with
BOS 0 had the lowest C4 levels of all groups. Al-
though complement levels deplete during acute
exacerbations of autoimmune and rheumatological
diseases, a broad variety of chronic inflammatory dis-
ease states including myocardial inflammation, pan-
creatic carcinoma, and age-related macular degeneration
are associated with higher levels of complement [46-50].
Similarly, our findings suggest that higher complement
levels present in higher stages of BOS may coincide with
chronic inflammation.
There were several limitations to this study. Regarding
the immunohistochemistry, the number of samples was
limited, and analysis of normal lung tissue was limited by
lack of availability from surgical biopsies often performed
for diagnosis of lung disease. Transbronchial biopsies would
be an alternative, but given the low yield for detecting BOS,
was not one of the study’s initial objectives. Nevertheless,
transbronchial biopsies would be useful to show the ab-
sence of MBL in those patients without BOS. The small
numbers of patients in each group may warrant a larger
analysis to fully confirm the findings, and the majority of
patients transplanted harbored cystic fibrosis. In this regard,
these data including mostly CF patients amplifies the com-
plex role of MBL in biology and disease. MBL-2 acts as a
gene modifier for CF disease and while MBL deficiency
portends worse CF disease pre-transplant [51], likely related
to host defense, low levels post-transplant are protective,
highlighting the benefit of reduced innate immunity. We
measured MBL levels after transplantation on the assump-
tion that MBL is genetically determined and that levels do
not vary significantly, although MBL levels may vary within
a defined range during infection and inflammation as an
acute phase reactant. However, serial MBL levels in a renal
transplant group did not vary after transplant, as confirmed
by Ibernon and colleagues [52]. We did not analyze struc-
tural gene mutations of MBL nor polymorphisms, which
are associated with differential expression of MBL, for ex-
ample, to see if the MBL deficient patients had the LXP
promoter haplotype, which is associated with low serum
levels. Certainly haplotype identification would further de-
fine low MBL producers with a genetic susceptibility andpossibly those less likely to develop BOS after transplant.
Nevertheless, in other studies MBL levels alone were suffi-
cient to predict graft dysfunction after renal transplant
[33,34]. Lastly, low levels of MBL may confer improved sur-
vival remains to be elucidated. While MBL may bind to
antibody Fc portions adherent to basement membrane and
endothelial cell surfaces, MBL may also be involved in
opsonization, phagocytosis, and apoptosis [53]. The latter
set of functions would be carried out by macrophages
through calreticulin. MBL binds calreticulin [54] which
plays a role in antigen presentation [55] and serves as a trig-
ger for innate immune responses in autoimmunity [56], DC
maturation, and T cell responses [57]. Conceivably, less
functional uptake of antigen and apoptotic particles may
lessen alloimmune stimulus. Future studies may better ad-
dress the mechanism of MBL related graft injury, as part of
antibody-mediated rejection or alteration of antigen-
presentation through impaired apoptosis.
In conclusion, MBL may contribute to graft inflammation
and rejection, serving to prime adaptive immunity during
ischemia-reperfusion, recurrent acute lung allograft rejec-
tion, and bronchiolitis obliterans. If mannose binding lectin
is an active participant in lung allograft injury at the initi-
ation of ischemia reperfusion through the continuum of
acute and chronic lung allograft rejection, current practice
would be altered towards complement inhibition and
improved methods for detection of humoral rejection. Our
data suggests that MBL is deposited within critical vascular
endothelium, epithelial basement membrane structures,
colocalizing at sites which succumb to long-term fibrosis.
Moreover, elevated MBL in the peripheral blood of patients
with early to late stages of BOS may prove to be a bio-
marker for an increased risk of chronic graft injury. Reduc-
tion of MBL levels and the elucidation of MBL ligands
expressed by the lung allograft may provide targets for
therapeutic inhibition.
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